The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel coronavirus disease (COVID-19). Though vaccines and neutralizing monoclonal antibodies (mAbs) have been developed to fight COVID-19 in the past year, one major concern is the emergence of SARS-CoV-2 variants of concern (VOCs). Indeed, SARS-CoV-2 VOCs such as B.1.1.7 (UK), B.1.351 (South Africa), P.1 (Brazil), and B.1.617.1 (India) now dominate the pandemic. Herein, we found that binding activity and neutralizing capacity of sera collected from convalescent patients in early 2020 for SARS-CoV-2 VOCs, but not non-VOC variants, were severely blunted. Furthermore, we observed evasion of SARS-CoV-2 VOCs from a VH3-30 mAb 32D4, which was proved to exhibit highly potential neutralization against wild-type (WT) SARS-CoV-2. Thus, these results indicated that SARS-CoV-2 VOCs might be able to spread in convalescent patients and even harbor resistance to medical countermeasures. New interventions against these SARS-CoV-2 VOCs are urgently needed.
【저자키워드】 COVID-19, Antibody Response, SARS-CoV-2 variants, neutralizing mAb, convalescent sera, 【초록키워드】 coronavirus disease, Brazil, SARS-CoV-2, Vaccine, coronavirus, pandemic, VoC, B.1.351, neutralization, India, SARS-CoV-2 variant, Intervention, novel coronavirus disease, severe acute respiratory syndrome Coronavirus, variants, Novel coronavirus, global pandemic, Spread, Convalescent patients, South Africa, SARS-CoV-2 variants, B.1.1.7, P.1, B.1.617.1, sera, VOCs, neutralizing capacity, respiratory, mAbs, neutralizing monoclonal antibodies, convalescent patient, neutralizing monoclonal antibody, mAb, binding activity, acute respiratory syndrome, Medical countermeasures, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, wild-type, collected, caused, indicated, New, VH3-30, 【제목키워드】 SARS-CoV-2, VH3-30,